Oxalo Therapeutics, Inc.
Chicago, IL · Founded 2018 · CIK 0001739172 · Biotech · Private
Oral peptide therapeutic to reduce urinary oxalate levels and prevent kidney stone formation
oxalotherapeutics.com →- Grants
- $4.5M
- 5 awards
- Sector median: 1
- Raised
- $250K
- 1 Form D · Jun 2018
- 100 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $250,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a peptide-based oral drug to prevent kidney stones | $299,998 | |
| Federal grant | National Science Foundation · Phase I · STTR Phase I: Developing a novel drug delivery system to enable an oral peptide based drug for kidney stones | $224,995 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a peptide-based oral drug to prevent kidney stones | $1,999,993 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing a peptide-based oral drug to prevent kidney stones | $999,995 | |
| Federal grant | National Science Foundation · Phase II · STTR Phase II: Developing a novel drug delivery system to enable an oral peptide-based drug for kidney stones | $999,999 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2615 | HB THERAPEUTICS, INC. | — | — |
| 2616 | NuRevelation, LLC | — | $250K |
| 2617 | Impact Proteomics, LLC | — | $250K |
| 2618 | Oxalo Therapeutics, Inc. | — | $250K |
| 2619 | Repertoire Immune Medicines | — | — |
| 2620 | KarnaTeq, Inc. | — | $250K |
| 2621 | ROME Therapeutics | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Hatim HassanDirector · Executive Officer
- Yang ZhengDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.